Past and current deal flow

Series A/B investor specializing in biotech investment is crucial as we advance healthcare innovation, particularly in areas like biobank services and clinical trials for consumer health products.

A Series B investor often plays a crucial role in funding biobank services, which are essential for advancing biotech investment. This investment can lead to innovative solutions in clinical trials and the development of consumer health products, ultimately driving healthcare innovation.

As a Series B investor, I focus on funding biotech investment opportunities that advance healthcare innovation. My interests include companies engaging in clinical trials and those developing consumer health products that utilize biobank services to enhance patient outcomes.

As a Series B investor, I focus on funding biotech investment opportunities that advance healthcare innovation. My interests include companies engaging in clinical trials and those developing consumer health products that utilize biobank services to enhance patient outcomes.

A Series A investor plays a crucial role in funding biobank services that support biotech investment, particularly in the areas of clinical trials and the development of consumer health products. Their contributions are vital for driving healthcare innovation forward.

PIPE investors play a crucial role in funding biobank services and biotech investments, especially as they pertain to innovative clinical trials and the development of consumer health products, driving advancements in healthcare innovation.

A Series A investor plays a crucial role in financing companies that focus on healthcare innovation, particularly in areas like biobank services and biotech investment. Their support is vital for businesses aiming to advance clinical trials and develop consumer health products, ultimately contributing to improved health outcomes.

AllianceXPartners is a royalty-and-warrant platform that focuses on funding confirmatory clinical trials for distressed US biotechs, particularly those with underfunded late-stage clinical programs. In the realm of biotech investment, the platform takes a synthetic royalty and a warrant in exchange for delivering FDA-usable data at no additional cash cost to the company. This approach not only supports healthcare innovation but also enhances the potential of consumer health products through effective biobank services.

A site management organization providing fast study start-up, predictable patient enrollment, and centralized quality control for sponsors and CROs in clinical trials — reducing operational risk from feasibility through inspection-readiness. Our services also support biobank services that are essential for biotech investment and advancements in consumer health products, driving healthcare innovation.

At Khepri, we're revolutionizing the landscape of pet care with a singular focus on improving the lives of aging companions. By integrating cutting-edge biobank services and engaging in biotech investment, we aim to enhance both the lifespan and quality of life for pets. With Khepri, we're not just adding years to pets' lives; we're adding life to their years through innovative consumer health products and advancing healthcare innovation. Together, we're redefining what it means to age gracefully in the animal kingdom, as we also pave the way for clinical trials that will ensure our companions age healthily.

We are building the largest Central Asian biobank, offering advanced biobank services to enhance healthcare innovation. Our mission is to help biotech investment firms understand complex biology by providing connections to patients globally, high-quality biospecimens, and ML-ready datasets. We support both pre-clinical and clinical trials with a keen focus on underrepresented geographic regions and diverse patient populations, which are essential for developing consumer health products. Currently, we are raising our Seed/Series A round.

Currently, there are no widely available consumer health products on the market that effectively eliminate bad bacteria while preserving the beneficial bacteria essential for a healthy microbiome. At our company, we leverage bacteriophage proprietary technology to target harmful bacteria and restore balance to microbiomes, contributing to ongoing healthcare innovation. Our focus aligns with the future of biotech investment, as we plan to expand our offerings through clinical trials and biobank services, ensuring our products are accessible to consumers.